The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.
The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.
Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.
Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.
Real-world data show comparable patient reported functional outcomes and health-related quality of life between nonmetastatic prostate cancer patients who were treated with moderately hypofractionated or conventionally fractionated radiation therapy.
A behavioral intervention to increase vegetable consumption does not reduce the risk for disease progression over 2 years in men with early-stage prostate cancer undergoing active surveillance, phase 3 study data show.
Biochemical relapse-free survival and overall survival rates are comparable in men with localized prostate cancer who start androgen-deprivation therapy before or at the same time as dose-escalated prostate radiotherapy, phase 3 study data show.
Baseline prostate-specific antigen levels in men screened between the ages of 55 and 60 years are significantly associated with long-term risk for clinically significant prostate cancer, shows an analysis of data from the PLCO Cancer Screening Trial.
Men with favorable- and unfavorable-risk prostate cancer who undergo prostatectomy report worse urinary incontinence at 5 years than men treated with other contemporary management options, US research shows.
Pembrolizumab monotherapy shows activity against both RECIST-measurable and bone-predominant treatment-refractory metastatic castration-resistant prostate cancer, results of the KEYNOTE-199 phase 2 trial show.
Prostate cancer has undergone “reverse migration” away from indolent disease and toward more aggressive presentation in the USA following recommendations against prostate-specific antigen screening, say researchers.
Researchers have been unable to show that single-dose radiotherapy is not inferior to multifraction radiotherapy in terms of ambulatory status in patients with metastatic prostate, lung, or breast cancer and spinal cord or cauda equina compression.
DSTP3086S, a humanized immunoglobulin G1 monoclonal antibody that targets six-transmembrane epithelial antigen of the prostate 1 has shown promising results in a phase 1 study of metastatic castration-resistant prostate cancer.
Overall survival rates among men receiving cabazitaxel for metastatic castration-resistant prostate cancer are lower in everyday oncology practice than previously observed in clinical trials, French study data show.
A sequencing strategy that uses abiraterone acetate plus prednisone followed by enzalutamide, rather than the opposite, provides the greatest clinical benefit to patients with newly diagnosed metastatic castration-resistant prostate cancer, researchers report.